Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
298 Leser
Artikel bewerten:
(1)

IDTechEx on Materials Informatics: Choosing a Successful Strategic Approach

BOSTON, Aug. 27, 2020 /PRNewswire/ -- Materials informatics is quickly becoming one of the most significant areas of interest for chemical and material companies. There have been significant early adopters, notable news stories, internationally renowned consortia established, large funding rounds, and still many yet to get started. Navigating a successful path is challenging, a misstep could have a large implication on cost and competitive advantage.

Source: Image depicting the different materials informatics companies. For more information see

There are many facets to materials informatics and many routes for a company to engage with this area. IDTechEx has written a brand-new report on Materials Informatics; this technical industry assessment provides the reader with primary interview-based profiles of the key technology providers, case studies across a wide range of application areas, and roadmaps & outlooks for the rate and scale of adoption.

For more details on what materials informatics encompasses and why an inflexion point is approaching see previous articles and the market report.

For a company wanting to use materials informatics there are three main approaches: partner with a company, join a public-private consortium, or go it alone and develop the capabilities in house.

The external MI players can come from numerous starting points, as outlined in the figure below. Dedicated MI companies have the advantage of years of experience and a product or service already well-tailored to the needs. Many have received notable investments and built a software team that is impossible to replicate overnight. The main downside is that to gain the full benefit of materials informatics then these systems need to be deeply embedded into all parts of a company's operations, including historic data, the point-of-entry for new data, and for research project scoping and activity. This brings three challenges: (1) data security is essential (2) confidence that the external company will exist for a long time (most are start-ups and most start-ups fail) (3) how to pick the right company. Then there is also the cost and the impact to a company in the long-term never builds up sufficient internal know-how and capabilities. Many just cherry-pick certain projects to carry-out which is beneficial but does not reach the full potential.

The MI experience and tailored offerings are driving many notable use-cases. The likes of Citrine Informatics, Uncountable, Kebotix, Intellegens, and many more can already boast a strong line-up of impressive customers. Many offer complete packages with subscription platforms for this data capture and analysis, this can have data repositories, proprietary algorithms, and even retrosynthesis predictors all integrated. Although subscription or research projects are the most typical form of engagements, others have established royalty-based agreements or use their expertise to develop IP that they subsequently license. Then there is also the option for MI players to become a licensing company with a strong advanced materials portfolio and for end-users to offer MI as a service.

The IDTechEx market report, "Materials Informatics 2020-2030", provides detail of these companies and their partnerships through a series of primary interviews.

Geographically, many of the end-users embracing this technology are Japanese companies, many of the emerging external companies are from the USA, and the most notable consortia and academic labs are split across Japan and the USA. In 2011, The Obama administration in the US launched the Materials Genome Initiative (MGI); a large proportion of the work coming out of the USA has links to this initiative and in many cases direct roots from this initiative.

Working with a public-private consortium is another common approach in this field. The benefits are lower financial investments, shared knowledge, access to a broad range of researchers, and opportunities to develop in-house capabilities. The negatives are also highly evident with less privacy, in some cases direct competitors working side-by-side, and less targeted projects. NIMS, in Japan, and NIST, in the USA, are national labs central to these consortia and much of the work globally.

Finally, there is the choice to completely build the capabilities in-house. This overcomes all the challenges previously outlined but is certainly not straightforward. To build this internally requires a large amount of investment and recruitment in areas not traditionally core to the company, bringing with it an element of risk and a longer time to see any results. Many of the external companies work on projects to improve their in-house capabilities and some, such as Enthought, provide dedicated training and custom tools to help companies become self-sufficient.

Navigating the best approach to adopting materials informatics is challenging. The technology is reaching a stage of maturity that real success stories are being seen and more end-users are looking to engage. There are pitfalls and hurdles at every stage. The IDTechEx report, "Materials Informatics 2020-2030", helps you understand the status and outlook for this market, seeing the potential in different sectors and for different projects.

For more information on this report, please visit www.IDTechEx.com/MaterialsInformatics or for the full portfolio of related research available from IDTechEx please visit www.IDTechEx.com/Research.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact research@IDTechEx.com or visit www.IDTechEx.com.

Media Contact:

Natalie Moreton
Digital Marketing Manager
press@IDTechEx.com
+44(0)1223 812300

IDTechEx Logo

Photo: https://mma.prnewswire.com/media/1244770/IDTechEx_MI.jpg

Logo: https://mma.prnewswire.com/media/478371/IDTechEx_Logo.jpg

© 2020 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.